A Study of JNJ-99220732 in Participants With Advanced or Metastatic Solid Tumors
A Phase 1 Trial of JNJ-99220732 in Participants With Advanced or Metastatic Solid Tumors
The purpose of this study is to find out how safe and well-tolerated JNJ-99220732 is and to find out the most suitable dose ([putative] recommended phase 2 dose [pRP2D] regimen[s]) of JNJ-99220732 (Part 1-Dose Escalation). Also, to find out how safe and well-tolerated JNJ-99220732 is at the pRP2D regimen(s) as determined in Part 1 (Part 2- Dose Expansion).
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Study Contact
- 电话号码:844-434-4210
- 邮箱:Participate-In-This-Study1@its.jnj.com
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion criteria:
- Histological or cytological diagnosis of locally advanced, or metastatic solid tumor, received greater than or equal to (>=) 1 prior line of therapy for recurrent or metastatic disease; progressed or relapsed after or be intolerant to standard therapy approved for the specific tumor type. Participants who actively decline available standard of care therapies are eligible upon documentation of their refusal.
i. Participants with NSCLC must not have known actionable driver alteration for which a targeted therapy is available.
ii. Demonstrated radiographic progression on most recent tumor assessment imaging
- Participants entering the study must have >=1 measurable lesion as defined by response evaluation criteria in solid tumors (RECIST) version 1.1 that has not been previously irradiated
- Body weight >=35 kilogram (kg) and body mass index (BMI) >=18 kilogram per square meter (kg/m^2)
- Eastern cooperative oncology group (ECOG) performance status of 0 or 1
- Must provide informed consent as described in protocol which includes compliance with the requirements and restrictions listed in the protocol and in the informed consent form (ICF)
Exclusion criteria:
- Active central nervous system (CNS) involvement with the exception of brain metastases that are clinically stable and asymptomatic for greater than (>)2 weeks off treatment and who are off or receiving low-dose corticosteroid treatment for at least 2 weeks prior to first dose of study treatment
- Any other malignancy diagnosis other than the disease under study within 2 years prior to the first dose of study treatment, except for squamous and basal cell carcinoma of the skin, non-muscle invasive bladder cancer, or any malignancy considered cured or has minimal risk of recurrence within 1 year of first dose of study treatment
- Had major surgery within 14 days prior to first dose of study treatment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to participate in the trial
- External beam radiation therapy to soft tissue lesions within 14 days prior to start of study treatment
- History of solid organ or allogeneic hematopoietic stem cell transplant (HSCT)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:JNJ-99220732 (Part 1 and Part 2)
Participants will receive escalating doses of JNJ-99220732 to identify the (putative) recommended phase 2 dose (pRP2D) regimen(s) in Part 1 (dose escalation) of the study. In Part 2 (dose expansion), participants will receive JNJ-99220732 at the pRP2D regimen(s) determined in Part 1 until lost to follow-up, withdrawal of consent, start of subsequent anticancer therapy, completion of the post treatment follow-up or the sponsor decides to stop the trial, whichever occurs first. |
JNJ-99220732 will be administered intravenously. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants with Adverse Events (AE) by Severity
大体时间:Up to 3 years 2 months
|
An AE is any untoward medical occurrence in a clinical trial participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. An assessment of severity grade will be made by the investigator according to the National cancer institute common terminology criteria for Adverse Events (NCI-CTCAE version 6.0) using the standard grades as follows: Grade 1- Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2- Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental activities of daily living (ADL); Grade 3- Severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4- Life-threatening consequences; urgent intervention indicated; Grade 5- Death related to adverse event. |
Up to 3 years 2 months
|
|
Part 1: Number of Participants with Dose Limiting Toxicities (DLTs)
大体时间:Up to 21 days
|
A DLT is defined as any adverse event that is not clearly due to the underlying disease or extraneous causes that occurs during the DLT period. It includes any toxicity resulting in permanent treatment discontinuation or a delay in dosing of greater than (>)14 days, any Grade 5 toxicity and any death not clearly due to underlying disease or non-study treatment-related cause, high-grade hematological and non-hematological toxicities. |
Up to 21 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Serum Concentration Time Profile of JNJ-99220732
大体时间:Up to 3 years 2 months
|
Serum concentrations of JNJ-99220732 over time will be reported. |
Up to 3 years 2 months
|
|
Maximum Observed Concentration (Cmax) of JNJ-99220732
大体时间:Up to 3 years 2 months
|
Cmax of JNJ-99220732 will be reported. |
Up to 3 years 2 months
|
|
Trough Concentration (Ctrough) of JNJ-99220732
大体时间:Up to 3 years 2 months
|
Ctrough of JNJ-99220732 will be reported. |
Up to 3 years 2 months
|
|
Time to Maximum Concentration (Tmax) of JNJ-99220732
大体时间:Up to 3 years 2 months
|
Tmax of JNJ-99220732 will be reported. |
Up to 3 years 2 months
|
|
Area Under the Concentration-Time Curve from Time Zero to Last Measured Time Point (AUC 0-tau) of JNJ-99220732
大体时间:Up to 3 years 2 months
|
AUC0-tau of JNJ-99220732 will be reported. |
Up to 3 years 2 months
|
|
Accumulation Ratio of JNJ-99220732
大体时间:Up to 3 years 2 months
|
Accumulation ratio of JNJ-99220732 will be reported. |
Up to 3 years 2 months
|
|
Number of Participants with Anti-Drug Antibodies Against JNJ-99220732
大体时间:Up to 3 years 2 months
|
Number of participants with anti-drug antibodies against JNJ-99220732 will be reported. |
Up to 3 years 2 months
|
|
Objective Response Rate
大体时间:Up to 3 years 2 months
|
Objective Response Rate (ORR) is defined as percentage of participants with best objective response of complete response (CR) or partial response (PR) based on response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) criteria. |
Up to 3 years 2 months
|
|
Disease Control Rate (DCR)
大体时间:Up to 3 years 2 months
|
DCR is defined as the percentage of participants who achieve a confirmed best overall response of CR, PR, or stable disease (SD) based on RECIST version 1.1. |
Up to 3 years 2 months
|
|
Radiographic Progression-Free Survival (rPFS)
大体时间:Up to 3 years 2 months
|
Radiographic PFS was defined as the time (in months) interval from first dose to the first date of radiographic progression or death. Radiographic progression included progression by bone scan, defined as at least 2 new lesions on bone scan and progression of soft tissue lesions by computed tomography (CT) or magnetic resonance imaging (MRI) (according to RECIST v.1.1 criteria). |
Up to 3 years 2 months
|
|
Duration of Response (DOR)
大体时间:Up to 3 years 2 months
|
DOR is defined as time from date of first documented response (CR/PR) until date of first documented progressive disease (PD) or death, whichever occurs first (according to RECIST v.1.1 criteria). |
Up to 3 years 2 months
|
合作者和调查者
调查人员
- 研究主任:Janssen Research & Development LLC Clinical Trial、Janssen Research & Development, LLC
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 99220732STM1001
- 2026-527759-24-00 (注册表标识符:EUCT number)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.